EGFRMUTANT STAGE IIIB/C OR IV NON-SQUAMOUS NSCLC

Clinical trials for EGFRMUTANT STAGE IIIB/C OR IV NON-SQUAMOUS NSCLC explained in plain language.

Never miss a new study

Get alerted when new EGFRMUTANT STAGE IIIB/C OR IV NON-SQUAMOUS NSCLC trials appear

Sign up with your email to follow new studies for EGFRMUTANT STAGE IIIB/C OR IV NON-SQUAMOUS NSCLC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

New combo shows promise for Drug-Resistant lung cancer

Disease control Completed

This study tested a combination of two immunotherapy drugs (atezolizumab and bevacizumab) plus chemotherapy in 95 people with a specific type of advanced lung cancer (EGFR-mutant non-small cell) that had stopped responding to standard targeted pills. The goal was to see if this n…

Matched conditions: EGFRMUTANT STAGE IIIB/C OR IV NON-SQUAMOUS NSCLC

Phase: PHASE2 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control

Last updated May 17, 2026 09:09 UTC

EGFRMUTANT STAGE IIIB/C OR IV NON-SQUAMOUS NSCLC

Get alerted when new EGFRMUTANT STAGE IIIB/C OR IV NON-SQUAMOUS NSCLC trials appear

New combo shows promise for Drug-Resistant lung cancer